Latest Protease inhibitors Stories
- RUBY-I evaluates treatment-naïve, non-cirrhotic, genotype 1 chronic hepatitis C patients with severe renal impairment VIENNA, April 25, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV)
As well as results from its Pivotal Phase 3 C-EDGE Programme Evaluating Grazoprevir/Elbasvir Showing High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus
- AbbVie's investigational, interferon and ribavirin-free treatment in Japan consists of a 12-week, two direct-acting antiviral, fixed-dosed combination of paritaprevir/ritonavir with ombitasvir, dosed
- 29 abstracts, including sub-analyses of AbbVie's approved treatment of VIEKIRAX® + EXVIERA®, as well as new data from Phase 3b development program and AbbVie's HCV pipeline compounds NORTH
- In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1), TURQUOISE-I, using VIEKIRA PAK with ribavirin (RBV), demonstrated sustained
JERUSALEM, February 19, 2015 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen TITUSVILLE, N.J., Jan.
DALLAS, January 23, 2015 /PRNewswire/ -- LifeScienceIndustryResearch.com adds Hepatitis C Global Clinical Trials Review, H2, 2014 as well as Hepatitis C Market & Forecast,
CORK, Ireland, December 29, 2014 /PRNewswire/ -- -- Two Companies to also Collaborate on the Further Development of Complera(R), Marketed